Stay updated on Olpasiran Study: Clinical Trial for Lipoprotein(a) Reduction
Sign up to get notified when there's something new on the Olpasiran Study: Clinical Trial for Lipoprotein(a) Reduction page.

Latest updates to the Olpasiran Study: Clinical Trial for Lipoprotein(a) Reduction page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe record describes Amgen’s Phase 2 olpasiran study, including its eligibility criteria, treatment arms, outcomes, and study locations. It also provides publications, study documents, and information about individual participant data sharing.SummaryDifference73%

- Check19 days agoChange DetectedThe ClinicalTrials.gov footer revision label changes from v3.7.2 to v3.8.0, while the study record remains behind a 403 Forbidden page.SummaryDifference0.2%

- Check25 days agoChange DetectedA banner announces updates to NIH websites and a terminology transition from “Artificial Intelligence” to “Super Intelligence.”SummaryDifference1%

- Check32 days agoChange DetectedThe footer revision label changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check39 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check60 days agoChange DetectedThe study page now displays a 403 Forbidden error instead of the study details. A Home button is shown, indicating the page is currently inaccessible.SummaryDifference19%

Stay in the know with updates to Olpasiran Study: Clinical Trial for Lipoprotein(a) Reduction
Enter your email address, and we'll notify you when there's something new on the Olpasiran Study: Clinical Trial for Lipoprotein(a) Reduction page.